NCT04888741 - Methods of T Cell Depletion Trial (MoTD) | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic SyndromesNon Hodgkin LymphomaHodgkin LymphomaMultiple MyelomaChronic Myelogenous LeukemiaMyelofibrosis

Interventions

DRUG

Thymoglobulin

GVHD prophylaxis

DRUG

Cyclophosphamide

Post transplant cyclophosphamide strategy for GVHD prophylaxis

DRUG

Cyclosporine

immunosuppressant

DRUG

Sirolimus

immunosuppressant

DRUG

Mycophenolate Mofetil

immunosuppressant

Trial Locations (15)

CF14 4XW

RECRUITING

University Hospital of Wales, Cardiff

B15 2GW

RECRUITING

Queen Elizabeth Hospital, Birmingham

BS2 8ED

RECRUITING

Bristol Haematology and Oncology Centre, Bristol

CB2 0QQ

RECRUITING

Addenbrookes Hospital, Cambridge

G51 4TF

RECRUITING

Queen Elizabeth Hospital Glasgow, Glasgow

LS9 7TF

RECRUITING

St Jame's University Hospital, Leeds

NW1 2BU

RECRUITING

University College London Hospital, London

SE5 9RS

RECRUITING

King's College Hospital, London

W12 0HS

RECRUITING

Hammersmith Hospital, London

M13 9WL

RECRUITING

Manchester Royal Infirmary, Manchester

M20 3QH

RECRUITING

The Christie, Manchester

NE7 7DN

RECRUITING

Freeman Hospital, Newcastle upon Tyne

NG5 1PB

RECRUITING

Nottingham City Hospital, Nottingham

OX3 7LE

RECRUITING

Churchill Hospital, Oxford

PL6 8DH

RECRUITING

Derriford Hospital, Plymouth

All Listed Sponsors

collaborator

IMPACT (funded by NHS Blood & Transplant, Anthony Nolan and Leukaemia UK)

UNKNOWN

lead

University of Birmingham

OTHER